Overview
- In a study of more than 12,000 patients presented Saturday at the American Heart Association meeting in New Orleans, Repatha reduced major cardiovascular events by 25% versus standard care.
- The injected therapy cut the risk of a first heart attack by 36% in participants who had not previously had a heart attack or stroke.
- The trial reported a 21% relative reduction in cardiovascular death, which did not reach statistical significance.
- The FDA in August expanded Repatha’s label to include adults at increased risk due to uncontrolled LDL cholesterol, removing the prior requirement for established cardiovascular disease.
- Amgen recently began U.S. direct-to-consumer cash sales at $239 per month and reported year-to-date sales up 33% to $2.15 billion, while Merck plans to present Phase 3 data for an oral PCSK9 candidate at the same meeting.